Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 and ED95 of remifentanil to suppress bronchoscopy response under ciprofol sedation
ChiCTR2300077720Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Nov 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remifentanil in procedural pain, Procedural anxiety and Tracheal response (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Tracheal response rate during bronchoscopy examination. Started Nov 2023; status: recruiting.
02
Drugs
remifentanil
03
Conditions
procedural painProcedural anxietyTracheal response
Beyond the preview
Go deeper on ChiCTR2300077720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077720.